Urokonic Acid
Urokonic Acid Uses, Dosage, Side Effects, Food Interaction and all others data.
Urokonic Acid presents the molecular formula of 3-acetamidol-2,4,6-triiodobenzoic acid and it is the first monomeric ionic compound used as an X-ray contrast agent. It was first synthesized by Wallingford in 1953 and it was filled in the FDA by the Johnson & Johnson subsidiary, Cilag Chemie AG, on February 8th, 1978. Urokonic Acid presents, in the FDA records, a category of drug substance with an inactive status.
| Trade Name | Urokonic Acid |
| Generic | Acetrizoic acid |
| Acetrizoic acid Other Names | Acide acetrizoique, Urokonic acid |
| Type | |
| Formula | C9H6I3NO3 |
| Weight | Average: 556.864 Monoisotopic: 556.74818 |
| Protein binding | The radiographic agents such as acetrizoic acid are carried free in plasma in which less than 5% of the injected dose is protein bound. |
| Groups | Withdrawn |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Urokonic Acid indication was to be used as a contrast agent for X-ray. Some information indicates its nephrotropic property as one of the characteristics for the utilization of acetrizoic acid. The X-ray imaging depends on the difference in tissue density which is provided by an X-ray attenuation between the area of interest and the surrounding tissue. The use of contrast agents will provoke a contrast enhancement or opacification and it will improve the differentiation of pathological processes from normal tissue.
How Urokonic Acid works
Iodine, a big component in acetrizoic acid, is an element with a high atomic density. This property causes attenuation of X-rays within the diagnostic energy spectrum. Thus, acetrizoic acid is a water-soluble and reasonably safe iodinated contrast agent that can be intravenously administered for clinical applications.
Toxicity
In preclinical studies performed in rodents, the LD50 after oral or intravenous administration was 2 g/kg and 8 g/kg respectively.
Elimination Route
After intravenous administration, acetrizoic acid gets largely distributed in the extracellular fluid space. Radiographic agents like acetrizoic agents present variations in the plasma concentration depending on the dose and injection rate. After 5 minutes of administration, about 80% of the administered dose will stay outside of the intravascular compartment. There are some exceptions to the diffusion, such as the brain, neural tissue and testes where the tight junctions do not allow extravascularization.
Half Life
When water-soluble contrast agents, such as acetrizoic acid, are administered, it is reported a half-life of approximate 4 hours.
Elimination Route
After intravenous administration, acetrizoic acid is mainly excreted unchanged by the kidney. The elimination pathway is handled by a glomerular filtration and concentration by tubular resorption of water. The excreted dose is of about 83% of the administered dose after 3 hours and of about 100% at 24 hours.
Innovators Monograph
You find simplified version here Urokonic Acid
